1. The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, May 2023 Subject(s): BuprenorphineBuprenorphine, Naloxone Drug CombinationGovernment RegulationMedicare Part DOpioid-Related Disorders -- drug therapyUnited States
2. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022 Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023 Subject(s): BuprenorphineDrug Users -- statistics & numerical dataGovernment RegulationMedicare Part D -- economicsOpiate Substitution TreatmentOpioid-Related Disorders -- drug therapyPrescription Drug Diversion -- statistics & numerical dataUnited States
